New England Journal of Medicine Publishes Phase 3 Trial Results for Inhaled Treatment Targeting Lung Scarring Disease

The world’s leading medical journal has released findings from two major phase 3 clinical trials testing an inhaled drug for idiopathic pulmonary fibrosis, a serious and progressive lung condition.

What the Journal Published

The New England Journal of Medicine — widely regarded as the most influential medical publication in the world — posted news of its 9 July 2026 issue this week, flagging several significant research papers landing at once.

Among the headline findings: two separate phase 3 trials, known as TETON-1 and TETON-2, examining the use of inhaled treprostinil as a treatment for idiopathic pulmonary fibrosis. The journal also published research into setmelanotide for an acquired condition, though full details of that third paper were not specified in the announcement.

What Is Idiopathic Pulmonary Fibrosis?

Idiopathic pulmonary fibrosis — IPF for short — is a chronic lung disease where the tissue deep in the lungs becomes damaged and scarred over time. “Idiopathic” simply means doctors don’t know the exact cause. The scarring makes it progressively harder to breathe, and there’s currently no cure. It tends to affect people over the age of 50, and men are diagnosed more often than women.

It’s a condition that doesn’t get talked about enough. But for those living with it, and for the families around them, it’s life-altering.

Treprostinil is a drug already used in the treatment of pulmonary arterial hypertension — high blood pressure in the arteries of the lungs. The TETON trials tested whether delivering it by inhalation could benefit people with IPF specifically. Phase 3 trials are the large-scale human studies that take place before a treatment can be considered for regulatory approval, so results at this stage carry real weight.

Why Phase 3 Results Matter

Getting a drug to phase 3 is a long road. These trials involve large numbers of participants, are rigorously controlled, and are designed to confirm whether a treatment actually works — and whether it’s safe — before health regulators like the Medicines and Healthcare products Regulatory Agency in the UK will consider approving it for widespread use.

Two parallel trials testing the same drug, published in the same issue of the NEJM, signals that researchers and the journal considered the evidence strong enough to present together. According to the journal’s announcement, both TETON-1 and TETON-2 results appear in the 9 July 2026 issue.

What Comes Next

Publication in the NEJM typically triggers review by regulatory bodies and health technology assessment organisations — in England, that means bodies like the Medicines and Healthcare products Regulatory Agency and the National Institute for Health and Care Excellence, which decides whether treatments are approved for NHS use.

If the trial results are positive and regulators agree, inhaled treprostinil could eventually become available to NHS patients in England, including those being treated through Kent and Medway NHS services. That process, however, takes time — often years from trial publication to prescription availability.

—

Key Takeaways

• The New England Journal of Medicine published two phase 3 trial results — TETON-1 and TETON-2 — examining inhaled treprostinil as a potential treatment for idiopathic pulmonary fibrosis in its 9 July 2026 issue
• Idiopathic pulmonary fibrosis is a progressive, incurable lung-scarring disease with no currently established cause, and new treatment options are actively being researched
• Phase 3 publication is a key step toward potential regulatory approval, though NHS availability would require further review by UK bodies including NICE

What This Means for Kent Residents

If you or someone you know has been diagnosed with idiopathic pulmonary fibrosis, it’s worth speaking to your GP or respiratory specialist about what current treatment options are available through the NHS — and asking about any clinical trials you might be eligible for. Research like the TETON trials doesn’t translate into NHS prescriptions overnight, but staying informed and maintaining an open conversation with your care team puts you in the best position. For general health queries, contact NHS 111, and in a medical emergency always call 999. The British Lung Foundation also offers support and information for people living with IPF and their families.